Those with chronic obstructive pulmonary disease (COPD), have a decreased production of IFN-β and are prone to acute infectious exacerbations that impair their quality of life.
COPD is a progressive disease that makes it hard to breathe. The majority of COPD is associated with long-term cigarette smoking, however long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD. Those with COPD have a decreased production of IFN-beta and are prone to acute infectious exacerbations that impair their quality of life.
In February 2018, Synairgen commenced a two-part Phase 2 trial to evaluate the potential of SNG001 in COPD. Part one was patients without symptoms of an RVI; part two was patients with a confirmed RVI.
The emergence of SARS-CoV-2 in early 2020 made it difficult to test this vulnerable patient population for virus and dose patients without potentially exposing them and research staff to SARS-CoV-2, so the trial was paused with 109 out of the targeted 120 patients recruited.
The Medicines and Healthcare Products Regulatory Agency (MHRA) allowed an unplanned interim analysis of the data on the grounds that it could generate data to support Synairgen’s SG016 trial of SNG001 in COVID-19 patients. Read more about SG015 at clinicaltrials.gov
In September 2022, Synairgen announced positive data from additional assessments of lung sputum samples from SG015. Read more here.